Nonclinical Safety Profile of Etelcalcetide, a Novel Peptide Calcimimetic for the Treatment of Secondary Hyperparathyroidism
Mark R. Fielden, Ian Pyrah(Amgen (United States)), Marie McKeon(BioReliance (United States)), James Tomlinson(University of Würzburg), Elise Lewis(Charles River Laboratories (United States)), Kurt A. Black(Amgen (United States)), Cameron Zimmermann(Amgen (United States)), Mark W. Griggs(MPI Research (United States)), Charles R. Dean(University of Virginia Health System), Carol Beevers(Covance (United Kingdom)), Satin G. Sawant(Amgen (United States)), Sarah Walter(UC San Diego Health System), Raju Subramanian(Gilead Sciences (United States))
Cited by 9
Related Papers
Spread of pathological tau proteins through communicating neurons in human Alzheimer’s disease
|Nature Communications|2020|539
Predicting Alzheimer’s disease progression using multi-modal deep learning approach
|Scientific Reports|2019|401
Basal forebrain degeneration precedes and predicts the cortical spread of Alzheimer’s pathology
|Nature Communications|2016|349
Glucuronidation of Statins in Animals and Humans: A Novel Mechanism of Statin Lactonization
|Drug Metabolism and Disposition|2002|346
Effects of Fibrates on Metabolism of Statins in Human Hepatocytes
|Drug Metabolism and Disposition|2002|325